MedPath

Study on the Recovery of Visual Perceptual Function Dysfunction in Patients With Diabetes

Not Applicable
Completed
Conditions
Diabetic Retinopathy (DR)
Visual Perception
Registration Number
NCT07095777
Lead Sponsor
The First Affiliated Hospital of Anhui Medical University
Brief Summary

Investigators aim to investigate the effectiveness of visual perceptual learning on visual perceptual function in participants with diabetic retinopathy and to provide novel therapeutic insights for visual functional rehabilitation in diabetic retinopathy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • moderate to severe non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy(PDR) prior to treatment(17)
  • prior pan retinal laser photocoagulation (PRP) at least 4 weeks before enrollment or vitreoretinal surgery at least 8 weeks before enrollment
  • stable clinical condition
  • best-corrected visual acuity (BCVA) > 1.0 logMAR (equivalent to a Snellen visual acuity of < 20/200)
  • clear refractive media
  • age ≤ 65 years
  • ability to comprehend the examination and training procedures
Exclusion Criteria
  • significant refractive media opacity
  • psychiatric disorders, chronic alcoholism and traumatic brain injury
  • new-onset vitreous hemorrhage, myopia, strabismus, amblyopia, glaucoma and macular diseases.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
contrast sensitivityFrom enrollment to the end of treatment at 12 weeks

The contrast sensitivity measurements include grating acuity, first-order motion stimulus perception sensitivity, second-order stationary stimulus perception sensitivity and second-order motion stimulus perception sensitivity, which represent the reciprocal of the contrast threshold.

Secondary Outcome Measures
NameTimeMethod
The Low Vision Quality of Life QuestionnaireFrom enrollment to the end of treatment at 12 weeks

This instrument has demonstrated high reliability and validity, and is sensitive to changes in visual function among individuals with vision loss. The minimum value is 25 and the maximum value is 125. Higher scores indicate better quality of life.

Trial Locations

Locations (1)

The First Affiliated Hospital of Anhui Medical University

🇨🇳

Hefei, Anhui, China

The First Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.